Enhancing Treatment Success in Osteoporosis: Optimising the Use of Teriparatide

Osteoporosis, a chronic metabolic bone disease affecting over 200 million people globally, is characterised by low bone mass and microarchitectural deterioration, leading to an increased risk of fractures.The prevalence and associated healthcare costs of osteoporosis are substantial, with an estimated 27.6 million individuals in the European Union (EU) living with the condition in 2010.Fractures, particularly vertebral and hip fractures, are linked to reduced health-related quality of life and increased mortality risk.While several efficacious osteoporosis treatments are available, none are suitable for permanent use.Instead, clinicians employ a sequential therapy approach in which patients transition between treatments, based on their individual risk factors.